See related research by Rungatscher *et al*., <http://ccforum.com/content/17/5/R245>

Lowering core temperature has complex and divergent effects on the myocardium, stimulating or inhibiting contractility and heart rhythm through several different mechanisms. The effects vary with the depth of hypothermia and are influenced by volume status, heart rate (which itself is affected by hypothermia), endocrine factors, and (crucially) extracellular and intracellular electrolyte concentrations. In general, moderate hypothermia (30 to 34°C) improves myocardial contractility whereas deep hypothermia (\<28°C) has the opposite effect. Under specific circumstances (presence of tachycardia, hypovolemia, or electrolyte disorders), moderate hypothermia can also cause myocardial dysfunction.

Electrolytes, particularly calcium, play a key role in maintaining myocardial contractility through mechanisms that are also temperature-dependent. In the previous issue of *Critical Care*, Rungatscher and colleagues \[[@B1]\] present the results of a study on a key issue affecting deep hypothermic circulatory arrest (DHCA): reversing calcium-mediated persistent myocardial dysfunction after rewarming from DHCA.

Moderate hypothermia (30 to 34°C) increases intracellular Ca^2+^ transients in a dose-dependent fashion, thereby increasing myocardial contractility \[[@B2]\]. However, deep hypothermia (\<28°C) can lead to intracellular calcium overload, especially when hypothermia is maintained for more than 30 minutes \[[@B3]-[@B5]\]. Intracellular hypercalcemia is corrected only slowly during and after rewarming from deep hypothermia, often leading to persistent myocardial dysfunction \[[@B3]-[@B5]\]. In addition, deep hypothermia can induce calcium desensitization, which usually develops during rewarming after DHCA. Diastolic relaxation, in turn, is rate-limited by removal of Ca^2+^ from the cytoplasm and the rate of cross-bridge detachment \[[@B6]\].

These issues are further complicated by hypothermia-induced changes in excretion of calcium and other electrolyte levels as well as on electrolyte shifts and changes in intracellular pH. Urinary electrolyte excretion can increase markedly during induction of hypothermia, and a pronounced intracellular shift of potassium, magnesium, phosphate, calcium, and (to a lesser extent) sodium will occur \[[@B7]-[@B9]\]. This intracellular shift is reversed when the patient is rewarmed \[[@B7],[@B8]\]. All this can have profound effects on the myocardium; this applies in particular to hypocalcemia, which can cause myocardial dysfunction, hypotension, arrhythmias, and failure to respond to drugs that act through calcium-mediated mechanisms (norepinephrine, dopamine, digoxin, and so on). Deficiencies of magnesium, potassium, and phosphate can also induce myocardial dysfunction and arrhythmias \[[@B7]\]. Conversely, intracellular influx of magnesium can help stabilize cellular membranes, improve intracellular energy management, and mitigate effects of calcium overload (which can occur during deep hypothermia but also during ischemia) \[[@B7],[@B8]\]. In addition, intracellular pH increases during hypothermia, potentially enhancing myocardial contractility by offsetting the calcium-desensitizing effect of hypothermia \[[@B10],[@B11]\]. Intracellular Na^+^ can also increase, leading to increased production of reactive oxygen species (ROS) in the mitochondria \[[@B12]\]. This may initially improve intracellular homeostasis through more effective intracellular signaling and energy management \[[@B13]\], but when the rise is excessive, ROS can severely damage intracellular structures \[[@B7],[@B13]\]. However, in yet another twist, mild hypothermia itself mitigates excessive ROS production, countering the potentially dangerous nitric oxide synthase toxicity \[[@B7]\].

Thus, the effects of moderate hypothermia on electrolytes in general and on calcium in particular are convoluted, with numerous and often conflicting effects on myocardial tissue. However, with deep hypothermia, some myocardial dysfunction will almost invariably occur, which is mediated to a substantial degree by intracellular calcium overload.

Epinephrin is the drug most commonly used to treat refractory hypotension in this situation. Rungatscher and colleagues \[[@B1]\] compared epinephrine with the calcium sensitizer levosimendan to reverse myocardial dysfunction after rewarming from DHCA in a rat model. They report that levosimendan was significantly more effective in reversing systolic and diastolic myocardial dysfunction, independent of volume status. Levosimendan also improved ventricular relaxation, better preserved myocardial ATP content, and reduced plasma lactate concentrations \[[@B1]\].

The same authors previously reported that levosimendan has better inotropic and lusitropic effects than epinephrine during rewarming from DHCA \[[@B14]\]. Others have published similar findings, with positive inotropic effects of levosimendan irrespective of the temperature.

Given these experimental data, levosimendan appears to be a highly promising drug to improve myocardial function during and after deep hypothermia, with a number of theoretical advantages over the commonly used epinephrine. The drug now needs to be evaluated in clinical studies, not just in DHCA but also for accidental hypothermia, in which rewarming is often complicated by major hemodynamic problems.

Given the mechanisms outlined above, hemodynamic effects of hypothermia can be hard to predict. Moderate hypothermia (30 to 34°C), induced under controlled conditions (euvolemia, preventing discomfort through sedation or other means, preserving normal serum electrolyte levels), will usually decrease heart rate, reduce risk of arrhythmias, markedly improve systolic function, and induce mild diastolic dysfunction. Under optimal conditions, the diastolic dysfunction has only minimal effects on myocardial performance, and the overall effect of cooling will be an improvement in myocardial contractility, increase in stroke volume, reduction in cardiac output (CO) because of the decrease in heart rate, and stabilization or slight increase in blood pressure \[[@B7]\]. Indeed, several clinical studies have reported the successful use of hypothermia to treat refractory cardiac shock \[[@B7]\]. The balance between metabolic supply and demand improves because the decrease in metabolic demand (7% to 10% per °C decrease in core temperature) exceeds the drop in CO \[[@B7]\].

However, under different conditions (especially the presence of tachycardia), myocardial contractility may be adversely affected even under moderate hypothermia \[[@B7]\]. Several studies have shown that increasing heart rate under normothermic conditions improves myocardial contractility and CO but that increasing heart rate under hypothermic conditions decreases myocardial contractility \[[@B7],[@B15]\]. There is also a dichotomy in temperature effect on heart rhythm: membrane stabilization and decreased risk of arrhythmias with moderate hypothermia, increased risk of arrhythmias with deep hypothermia (\<28°C) \[[@B7]\].

The results of the study by Rungatscher and colleagues \[[@B1]\] for deep hypothermia suggest that levosimendan could potentially also be used to reverse the mild diastolic dysfunction that occurs in many patients during moderate hypothermia. However, it is too early to recommend the use of this promising drug outside the context of clinical trials.
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